The Effect of Vitamin C Supplementation on Gut Microbiota Composition and Function in Healthy Adults

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Glasgow

About this trial

The aim of this dietary intervention study is to explore how vitamin C affects the bacteria that live in our gut. Vitamins are essential nutrients found in fruits and vegetables. Our bodies cannot make them on their own, but we need them to function correctly. Vitamins play various roles, including supporting the immune system and assisting with energy production. Some vitamins in our diet can reach the large intestine, where they may be used by gut bacteria to promote their growth. In this study, we aim to investigate how our gut bacteria interact with vitamin C and how this interaction affects their growth and activity.

For this study, participants will follow their habitual diet for one-week (run-in period), followed by two consecutive two-week supplementation periods in which they will first take a moderate dose (200 mg/day) and then a high-dose (1000 mg/day) of vitamin C. A final one-week period follow up period will involve a return to their habitual diet. Faecal, blood and urine samples will be collected at the start and end of each supplementation period to explore changes in gut microbiota composition, activity and markers of inflammation.

Eligibility criteria

Qualifiers

Healthy individuals aged 18-65 years with a BMI between 18.5-35 Kg/m2

Self-reported good health with no chronic conditions requiring regular medical care

Willing to provide blood, urine, and stool samples at multiple time points

Disqualifiers

Aged <18 or >65 years

Smoking

Chronic illness requiring regular medication or GP visits

Current or recent medication affecting gut transit or digestion

Trial design

Treatments tested in this trial

  • Moderate Vitamin C dose (200 mg)
  • High-dose vitamin C supplementation (1000 mg)
  • Habitual diet (run in period)

Treatment groups

23 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Glasgow

Lead sponsor

Professor Konstantinos Gerasimidis, University of Glasgow

Collaborator